← Back to Search

Treatment for Epidermolysis Bullosa

N/A
Recruiting
Research Sponsored by Krystal Biotech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

Eligible Conditions
  • Epidermolysis Bullosa
  • Dystrophic Epidermolysis Bullosa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Serious Adverse Events (AE)

Find a Location

Who is running the clinical trial?

Krystal Biotech, Inc.Lead Sponsor
13 Previous Clinical Trials
395 Total Patients Enrolled
5 Trials studying Epidermolysis Bullosa
105 Patients Enrolled for Epidermolysis Bullosa
~26 spots leftby May 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top